

DiaObesity2017 - Scientific Program

Wednesday 22 Nov 2017	
PRE-SUMMIT COURSE: EASO OMTF (Obesity Management Task Force) Teaching Course in Obesity Management *	
08:00-08:50	Gathering & Light refreshment - Supported by Novo Nordisk
08:50-09:00	Course Opening Nathalie Farpour-Lambert, Switzerland & Dror Dicker, Israel
09:00-09:30	Obesity as a disease Dror Dicker, Israel
09:30-10:00	Childhood obesity as a chronic disease Nathalie Farpour-Lambert, Switzerland
10:00-10:30	Motivational Interview – to whom, when & how? Batya Kornboim, Israel
10:30-11:00	Anti-Obesity medication – to whom, when & how? Gabriella Segal Lieberman, Israel
11:00-11:30	Gastroenterological tools for treating Obesity and Post Bariatric Surgery complications Sigal Fishman, Israel
11:30-12:00	Coffee Break/Commercial Exhibition
12:00-12:30	Bariatric/Metabolic Surgery – to whom, when & how? Hadar Spivak, Israel
12:30-13:00	Post Bariatric Surgery Treatment Dror Dicker, Israel
13:00-13:30	Evaluation & Questions/Answers & Course Summary
13:30-14:30	Lunch

*Participants will be granted an official EASO OMTF Teaching Course Certificate

*** SUPPORTED BY NOVO NORDISK ***

Wednesday 22 Nov 2017	
DIAOBESITY OPENING PLENARY SESSION	
17:00-18:00	Registration
18:00-18:40	OPENING OF MEETING Ministry of Health, Israel
18:40-19:00	<i>STATE OF THE ART</i> - Childhood Obesity - How big is the problem, and how much is it going to cost us? Nathalie Farpour-Lambert, Switzerland
19:00-19:40	<i>STATE OF THE ART</i> - How should we change diabetes treatment guidelines in light of the new evidence? Itamar Raz, Israel
19:40-20:00	<i>STATE OF THE ART</i> - Nutrigenetics of obesity- are we there yet? Ruth Birk, Israel
20:00-20:20	<i>STATE OF THE ART</i> - How close are we to mimicking the effects of bariatric surgery without the use of a knife? Carel le Roux, Ireland
20:20-22:00	Welcome Reception

Thursday 23 Nov 2017	
STATE OF THE ART : BIG DATA IN DIAOBESITY	
08:20-08:40	<i>STATE OF THE ART</i> - What have we learned from Big Data -Obesity Ran Balicer, Israel
08:40-09:00	<i>STATE OF THE ART</i> - What have we learned from real world data in novel diabetes therapy? Avraham Karasik, Israel
SESSION 1: THE BRAIN AS A TARGET FOR OBESITY THERAPY	SESSION 2: NEW FRONTIERS IN DIABETES TREATMENT
09:00-09:30	Functional neuroimaging in the development of novel anti-obesity interventions Michael Stumvoll, Germany
09:30-10:00	Exploiting the intra-nasal administration route for central delivery of insulin and other hormones in obesity therapy. Manfred Hallschmid, Germany
10:00-10:30	Can we smell Obesity? Dror Dicker, Israel
10:30-11:00	Obesity, dysglycemia and cognitive decline: Evidence-based and current clinical practice for a bi-directional relationship Tali Cukierman-Yaffe, Israel
11:00-11:30	Coffee Break/Commercial Exhibition/Abstract Exhibition
SESSION 3: ADIPOSE TISSUES IN OBESITY	SESSION 4: DIABETES IN SPECIAL POPULATIONS & SITUATIONS
11:30-12:00	Visceral obesity and type 2 diabetes: time to align clinical practice/public health messages to the science Jean-Pierre Després, Canada
12:00-12:30	Can molecular and functional signatures of adipose tissue guide clinical obesity subtyping? Assaf Rudich, Israel
12:30-13:00	Lifestyle strategies for relieving the Cardiometabolic impact of obesity via adipose tissues' redistribution Iris Shai, Israel
13:00-13:10	Oral Abstract Presentation TBA
13:10-13:20	Oral Abstract Presentation TBA
13:20-13:30	Oral Abstract Presentation TBA
13:30-15:00	Lunch
14:00-15:00	<i>MASTER CLASS:</i> Chairs – Lilach Malatsky Israel & Batya Kornboim, Israel Assessing and managing Cardiometabolic risk at the workplace: making lifestyle habits vital signs Jean-Pierre Després, Canada
14:00-15:00	POSTER SESSION
15:00-15:20	<i>STATE OF THE ART</i> - How can we prevent weight regain? Luca Busetto, Italy
SESSION 5: ANTI-OBESITY MEDICATION	SESSION 6: FUNCTIONAL FOOD & DIAOBESITY
15:20-15:40	<i>STATE OF THE ART</i> - Obesity as a Disease Lee Kaplan, USA
15:40-16:10	Anti-Obesity medication – Present and Future Nick Finer, UK
16:10-16:40	The roll of CNS in Anti-Obesity medication Gabriella Liberman, Israel
16:40-17:00	REAL WORLD DATA-Liraglutide 3mg for the Treatment of Obesity Naim Shehadeh, Israel
17:00-17:30	What is the place of Anti-Obesity medication after bariatric surgery? Carel le Roux, Ireland
15:30-16:00	Novel mechanisms for the metabolic actions of green tea polyphenol Jeonga Kim, USA
16:00-16:30	The food preservative Propionic Acid as a metabolic disruptor. Amir Tirosch, Israel
16:30-17:00	TBA TBA, Israel

Friday 24 Nov 2017	
SESSION 7 : GUT MICROBIOTA AND DIAOBESITY	
08:30-09:00	Gut Microbiota manipulation in Obesity: promise and challenges Eran Elinav, Israel
09:00-09:30	Gut Microbiota: The importance of diversity Karine Clément, France
09:30-09:45	Coffee Break/Commercial Exhibition/Abstract Exhibition
SESSION 9: BARIATRIC SURGERY AND DIAOBESITY	SESSION 8: CHILDHOOD OBESITY
09:45-10:15	Sex hormones and brain reward in response to visual food cues Ram Weiss, Israel
10:15-10:35	Should we use anticoagulant after bariatric surgery? – Review on the new Israeli guidelines. Dorit Blickstein, Israel
10:35-10:50	Can bariatric surgery reduce mortality? Orna Reges, Israel
10:50-11:05	Hypoglycemia after bariatric surgery - how big is the problem? Dror Dicker, Israel
11:05-11:20	How can we predict Diabetes Remission after Metabolic Surgery? Judith Aron Wisniewsky, France
11:20-12:40	Does the Omega loop offer a better outcome than Roux-en-Y gastric bypass? Subhi M. Abu Abid, Israel
12:40-13:00	Should gastroenterology sleeve be the first line option for Bariatric Surgery? Hadar Spivak, Israel
13:00-13:20	PLENARY SESSION SUMMARY- What should be the 1 st line Metabolic/Bariatric Surgery? Nahum Beglaibter, Israel
13:20-13:30	SUMMIT SUMMARY & FAREWELL Organizers
13:30-14:30	Lunch

*** The Scientific Program is subject to changes